Brooks Laboratories Latest Share Price (BROOKS)
TODAY IN ONE LINE
With a market cap of ₹182.28 Cr., it trades at a P/E of 8.22. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Brooks Laboratories flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 42.3% and Profit up 498.0%
- ●Strong Return on EquityHealthy ROE of 20.0%
- ●Reasonable ValuationTrading at a moderate P/E of 8.2x
- ●High Promoter HoldingPromoters hold 52.6% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.06x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 16.6% outpacing sales growth of 3.9%
Latest Brooks Laboratories News
What changed recently?
Recent events, corporate actions, and announcements.
Brooks Laboratories Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Brooks Laboratories Limited, framed against the sector median so the premium or discount is obvious at a glance.
Brooks Laboratories Limited trades at a P/E of 8.22× and P/B of 1.65×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Brooks Laboratories Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Brooks Laboratories Limited — derived from the latest tape, not yesterday's close.
Brooks Laboratories Limited last traded at ₹69.58 with an intraday range of ₹69.01–₹71.89 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹69.58| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 77.07 | +7.49 | +10.76% |
| R3 | 74.19 | +4.61 | +6.63% |
| R2 | 73.04 | +3.46 | +4.97% |
| R1 | 71.31 | +1.73 | +2.49% |
| PIVOT | 70.16 | 0.58 | 0.83% |
| CURRENT | 69.58 | — | — |
| S1 | 68.43 | -1.15 | -1.65% |
| S2 | 67.28 | -2.30 | -3.31% |
| S3 | 65.55 | -4.03 | -5.79% |
| S4 | 62.67 | -6.91 | -9.93% |
BROOKS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Below opening range, showing Bearishness
Brooks Laboratories Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Brooks Laboratories Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Brooks Laboratories Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹182.28 Cr. and reported EPS of ₹7.32.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 83 | 86 ▲ 3.9% |
| Sales Growth YoY %Derived | 3.86% | 3.85% |
| Other Income | 1 | 1 ▲ 32.5% |
| Total Income | 83 | 87 ▲ 4.2% |
| 54 | 51 ▼ 5.6% | |
| Gross ProfitDerived | 28 | 35 ▲ 21.9% |
| Gross Margin %Derived | 34.50% | 40.49% |
| 24 | 28 ▲ 17.5% | |
| EBITDA (Operating Profit)Derived | 5 | 7 ▲ 42.9% |
| OPM %Derived | 5.98% | 8.23% |
| 3 | 2 ▼ 7.8% | |
| Profit Before Tax (PBT) | 3 | 6 ▲ 81.8% |
| 0 | — ▼ 100.0% | |
| Effective Tax %Derived | 5.49% | — |
| Total Profit for Period | -10 | 25 ▲ 346.6% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | -10 | 25 ▲ 346.6% |
| Net Profit Margin %Derived | -12.07% | 28.67% |
| PAT Growth YoY %Derived | 49.13% | 346.65% |
| Earnings Per Share (EPS ₹) | -3.38 | 8.34 ▲ 346.7% |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.0% |
| Share of Profit from Associates/JVs | -13 | 19 ▲ 244.6% |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▼ 67.8% |
| Total Expenses (incl. D&A & Interest) | 80 | 81 ▲ 1.1% |
| Material Cost % of RevenueDerived | 56.98% | 57.86% |
| Employee Cost % of RevenueDerived | 15.70% | 17.68% |
| Other Cost % of RevenueDerived | 12.82% | 14.57% |
| Interest Coverage (x)Derived | 3.25x | 6.55x |
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 77 | 91 ▲ 17.9% | 63 ▼ 30.6% | 79 ▲ 25.8% | 83 ▲ 3.9% | 86 ▲ 3.9% | |
| Sales Growth YoY %Derived | — | 17.90% | -30.60% | 25.76% | 3.86% | 3.85% | |
| Other Income | 1 | 1 ▲ 23.6% | 0 ▼ 77.6% | 1 ▲ 369.8% | 1 ▼ 7.6% | 1 ▲ 32.5% | |
| Total Income | 78 | 92 ▲ 18.0% | 63 ▼ 31.1% | 80 ▲ 26.9% | 83 ▲ 3.7% | 87 ▲ 4.2% | |
48 | 63 ▲ 32.0% | 51 ▼ 19.4% | 57 ▲ 11.9% | 54 ▼ 4.5% | 51 ▼ 5.6% | ||
| Gross ProfitDerived | 30 | 28 ▼ 4.7% | 13 ▼ 55.5% | 23 ▲ 81.4% | 28 ▲ 24.6% | 35 ▲ 21.9% | |
| Gross Margin %Derived | 38.41% | 31.06% | 19.94% | 28.77% | 34.50% | 40.49% | |
29 | 43 ▲ 46.3% | 39 ▼ 8.5% | 20 ▼ 49.6% | 24 ▲ 19.8% | 28 ▲ 17.5% | ||
| EBITDA (Operating Profit)Derived | 1 | -14 ▼ 2856.6% | -26 ▼ 84.0% | 3 ▲ 112.2% | 5 ▲ 53.5% | 7 ▲ 42.9% | |
| OPM %Derived | 0.67% | -15.77% | -41.80% | 4.05% | 5.98% | 8.23% | |
10 | 10 ▲ 2.0% | 9 ▼ 15.3% | 3 ▼ 70.4% | 3 ▲ 0.4% | 2 ▼ 7.8% | ||
| Profit Before Tax (PBT) | -9 | -24 ▼ 166.0% | -36 ▼ 49.7% | 2 ▲ 104.3% | 3 ▲ 105.3% | 6 ▲ 81.8% | |
10 | -5 ▼ 144.2% | -7 ▼ 59.7% | 0 ▲ 100.4% | 0 ▲ 576.4% | — ▼ 100.0% | ||
| Effective Tax %Derived | -115.55% | 19.19% | 20.47% | 1.67% | 5.49% | — | |
| Total Profit for Period | -19 | -19 ▲ 0.3% | -32 ▼ 64.5% | -20 ▲ 38.3% | -10 ▲ 49.1% | 25 ▲ 346.6% | |
| Less: Non-controlling Interests | — | -3 | -10 ▼ 224.9% | — ▲ 100.0% | — | — | |
| Net Profit (Owner's PAT)Derived | -19 | -16 ▲ 16.5% | -22 ▼ 33.5% | -20 ▲ 9.4% | -10 ▲ 49.1% | 25 ▲ 346.6% | |
| Net Profit Margin %Derived | -25.08% | -17.77% | -34.20% | -24.65% | -12.07% | 28.67% | |
| PAT Growth YoY %Derived | — | 16.45% | -33.52% | 9.35% | 49.13% | 346.65% | |
| Earnings Per Share (EPS ₹) | -7.38 | -6.17 ▲ 16.4% | -7.96 ▼ 29.0% | -7.46 ▲ 6.3% | -3.38 ▲ 54.7% | 8.34 ▲ 346.7% | |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 12.2% | 3 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -0 | — ▲ 100.0% | -3 | -21 ▼ 538.1% | -13 ▲ 38.5% | 19 ▲ 244.6% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▼ 39.4% | -0 ▼ 150.3% | -0 ▼ 31.8% | -0 ▲ 57.8% | -0 ▼ 67.8% | |
| Total Expenses (incl. D&A & Interest) | 87 | 116 ▲ 33.2% | 99 ▼ 14.4% | 79 ▼ 20.5% | 80 ▲ 1.7% | 81 ▲ 1.1% | |
| Material Cost % of RevenueDerived | 60.42% | 69.10% | 65.73% | 56.26% | 56.98% | 57.86% | |
| Employee Cost % of RevenueDerived | 18.60% | 21.03% | 27.44% | 13.26% | 15.70% | 17.68% | |
| Other Cost % of RevenueDerived | 19.14% | 25.80% | 34.30% | 11.46% | 12.82% | 14.57% | |
| Interest Coverage (x)Derived | -2.14x | -7.01x | -15.32x | 1.71x | 3.25x | 6.55x |
Brooks Laboratories segment analysis : revenue and profit mix.
Disclosed business segments at Brooks Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Brooks Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Brooks Laboratories Limited.
Our AI distills the core fundamental drivers supporting Brooks Laboratories Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Brooks Laboratories Limited's investment case rests on 7 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Brooks Laboratories has demonstrated a remarkable turnaround in its latest quarter, reporting a substantial 498.00% increase in net profit, reaching 9.58 Cr. This strong quarterly performance indicates improving operational efficiency and a positive shift in profitability.
The company has shown robust top-line growth, with quarterly sales increasing by an impressive 42.30% to 25.5 Cr. This significant sales expansion suggests growing market demand and effective business strategies.
Brooks Laboratories maintains a very healthy financial structure with a low debt-to-equity ratio of 0.08. This indicates minimal reliance on borrowed capital, providing financial stability and flexibility for future growth initiatives.
Promoter holding remains substantial at 52.62% as of 2025-09-01, reflecting strong confidence from the core management in the company's long-term prospects and strategic direction, aligning interests with shareholders.
Operating within the 'Pharmaceuticals' sector, Brooks Laboratories can capitalize on the robust and expanding global healthcare market. Increasing demand for medicines and healthcare services presents significant growth avenues for the company.
Key Risks.
The company's stock trades at a very high P/E ratio of 153.00, significantly above industry averages. This valuation suggests the stock might be overvalued, posing a risk for potential investors seeking reasonable entry points.
Brooks Laboratories exhibits negative returns on capital employed (-9.93%), equity (-12.20%), and assets (-9.33%). This indicates the company is not effectively generating profits from its capital and assets, a major concern.
The operating profit margin (OPM) stands at a negative -3.37%, indicating that the company's core operations are not generating sufficient profit to cover operating costs. This highlights a need for improved cost management.
The stock has experienced significant price volatility, dropping from a 52-week high of 203.00 to its current 106.00. Recent 5-day data also shows a decline, indicating potential investor apprehension and downward pressure.
The company currently offers a 0.00% dividend yield, meaning it does not distribute profits to shareholders. This might deter income-focused investors and suggests a focus on reinvestment or insufficient profitability for payouts.
Flip Conditions.
Valuation risk. a P/E above 11 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 15% would indicate weaker capital compounding.
Brooks Laboratories Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Brooks Laboratories Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Brooks Laboratories Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Brooks Laboratories Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Brooks Laboratories Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Brooks Laboratories Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Brooks Laboratories Limited stood at 59.7% of traded volume, against a 20-day average of 51.3%.
Brooks Laboratories announcements: results, concalls, ratings, M&A.
Filings Brooks Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Brooks Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 48 documents below.
Copy of Newspaper Publication
Please find enclosed herewith Addendum to the Notice of 24th Annual General Meeting.
Shareholders meeting
Addendum to the Notice of 24th Annual General Meeting of the Company.
Updates
Brooks Laboratories Limited has informed the Exchange regarding 'Intimation Of Record Date, E-Voting Dates And Book Closure Date'.
Copy of Newspaper Publication
Brooks Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Brooks Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Investor decks & rating reports.
Brooks Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Brooks Laboratories has declared, sequenced by announce and record date.
Brooks Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Brooks Laboratories Limited: business, sector, key facts.
What Brooks Laboratories Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Brooks Laboratories Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BROOKS, BSE: 533543.
Brooks Laboratories Limited is a pharmaceutical company headquartered in Mumbai, India, that was established in 2002. Its primary business revolves around the manufacturing and sale of a diverse range of pharmaceutical products both domestically within India and in international markets.
The company's product portfolio encompasses a broad spectrum of dosage forms designed to cater to various medical needs. This includes liquid and dry powder injections, a specialized area focusing on carbapenem dry powder injectables, which are likely used to treat serious bacterial infections. They also produce tablets, oral suspensions (liquids taken orally), dry syrups (syrups in powder form requiring reconstitution), and ophthalmic and otic preparations (eye and ear drops respectively).
The wide variety of dosage forms suggests Brooks Laboratories caters to a broad range of therapeutic areas. While the specific therapeutic categories aren't explicitly stated, the inclusion of carbapenem injectables indicates a focus on treating severe bacterial infections, while the presence of oral and topical formulations (tablets, syrups, eye/ear drops) demonstrates a broader commitment to various treatment needs.
Brooks Laboratories' business model centers on the production and distribution of its pharmaceutical products. The company's international presence suggests a commitment to exporting its products, indicating a strategy focused on both the domestic Indian market and global markets. The success of this business likely depends on factors such as manufacturing efficiency, regulatory compliance in multiple markets, effective distribution networks, and the ongoing development of new and improved pharmaceutical formulations.
In summary, Brooks Laboratories Limited is a significant player in the Indian pharmaceutical industry, actively engaged in manufacturing and distributing a diverse range of pharmaceutical products across multiple dosage forms and likely therapeutic areas. Their international reach and focus on injectable medications, particularly carbapenems, indicate a dedication to addressing significant medical needs both within India and globally.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Brooks Laboratories Limited (BROOKS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Brooks Laboratories Limited (BROOKS)?
The current share price of Brooks Laboratories Limited (BROOKS) is ₹69.58. Today, the stock has declined by ₹2.49 (3.45%), trading in a range of ₹69.01 to ₹71.89. The stock opened at ₹71.79 with a trading volume of 91,999 shares.
02Is Brooks Laboratories Limited stock a good investment for long-term?
Brooks Laboratories Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹182.28 Cr., P/E ratio of 8.22, ROE of 20.04%, and ROCE of -9.93%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Brooks Laboratories Limited stock?
The 52-week high price of Brooks Laboratories Limited (BROOKS) is ₹163.90, while the 52-week low is ₹36.30. Currently trading at ₹69.58, the stock is 91.68% above its 52-week low and 57.55% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Brooks Laboratories Limited stock at the current price?
Whether to buy Brooks Laboratories Limited stock at ₹69.58 depends on multiple factors. The stock is currently trading with a P/E ratio of 8.22 and P/B ratio of 1.65. Today's performance shows a loss of 3.45%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Brooks Laboratories Limited and when is the next dividend?
Brooks Laboratories Limited offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹69.58, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Brooks Laboratories Limited?
Brooks Laboratories Limited's key financial metrics include: P/E Ratio: 8.22, P/B Ratio: 1.65, ROE: 20.04%, ROCE: -9.93%, Dividend Yield: 0%, EPS: ₹7.32, Book Value: ₹33.30, and Debt-to-Equity: 0.06. The company's market cap stands at ₹182.28 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Brooks Laboratories Limited stock performing today in the market?
Brooks Laboratories Limited stock opened at ₹71.79 and is currently trading at ₹69.58, showing a decline of ₹2.49 (3.45%). The intraday high is ₹71.89 and low is ₹69.01. The trading volume stands at 91,999 shares, indicating moderate market participation today.
08What is the P/E ratio of Brooks Laboratories Limited and what does it indicate?
Brooks Laboratories Limited has a Price-to-Earnings (P/E) ratio of 8.22, which means investors are willing to pay 8.22 for every ₹1 of earnings. With an EPS of ₹7.32, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Brooks Laboratories Limited (BROOKS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.